Examining the effect of antipsychotic discontinuation in a large London cohort of patients with psychosis
Trifluoperazine is a routine treatment for chronic schizophrenia, which went through significant supply problems from around 2009 and was discontinued in 2011. Anecdotally switching to alternative medication appeared to lead to a number of relapses and hospitalisations. This study aims to examine if this did in fact occur in SLAM.